Clinical trials: Apatinib
Gastric Cancer
A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib showed good safety and efficacy as third-line therapy for advanced gastric cancer.We conducted this trial to investigate the safety and efficacy of…
- Trial name
- NCT03271073
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Recurrent/Metastatic Endometrial Cancer
Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
This study takes investigator-assessed Progression-Free Survival (PFS) as the primary endpoint, with plans to enroll 140 patients with advanced recurrent/metastatic endometrial cancer in a 1:1 ratio, randomized into an…
- Trial name
- A-CAPE (NCT06771154)
- Testing
- Adebelimab Combined with Apatinib, Adebelimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Gastric Cancer
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced…
- Trial name
- NCT03954756
- Testing
- Apatinib and PD1
- Volunteers
- 35 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
- Trial name
- NCT02596256
- Testing
- Apatinib, Docetaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Biliary Tract Cancer
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
This prospective real-world study aims to evaluate the effectiveness and safety of an alternating treatment regimen combining hepatic arterial infusion chemotherapy (HAIC) with systemic chemotherapy, with or without adebrelimab…
- Trial name
- NCT07569679
- Testing
- HAIC, Gemcitabine plus Cisplatin, Adebrelimab
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Air Force Military Medical University, China
Hepatocellular Carcinoma
A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma.
- Trial name
- HZ-T-PD1-APA (NCT03793725)
- Testing
- SHR1210, Apatinib
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence
- Trial name
- NCT04701060
- Testing
- Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital